Related Experiment Video
Updated: Jun 6, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Precision Oncology: 2024 in Review
Matteo Repetto1, Nicole Fernandez2, Alexander Drilon1,3
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract:
This article discusses the specific advances made in precision oncology in 2024. We comment on the evolving nature of predictive molecular events used to select patients who will most benefit clinically from treatment. We also discuss advances in the development of strategic treatment regimens for combination therapies, rational drug design of small-molecule inhibitors, and structurally informed drug repurposing.
Insights
Precision oncology in 2024 is advancing rapidly. Key developments include better patient selection using predictive molecular markers and improved combination therapies through rational drug design and repurposing.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Precision oncology aims to tailor cancer treatment to individual patients.
- Identifying predictive molecular events is crucial for effective patient selection.
- Advances in drug development are essential for improving therapeutic outcomes.
Purpose of the Study:
- To summarize key advances in precision oncology during 2024.
- To highlight evolving strategies in patient selection based on molecular markers.
- To discuss progress in combination therapies, small-molecule inhibitor design, and drug repurposing.
Main Methods:
- Review of recent literature and clinical trial data in precision oncology.
- Analysis of emerging predictive molecular biomarkers.
- Evaluation of novel therapeutic strategies including combination regimens and drug design.
Main Results:
- Significant progress in identifying and utilizing predictive molecular events for patient stratification.
- Advancements in developing strategic combination therapies.
- Innovations in rational drug design for small-molecule inhibitors and structure-informed drug repurposing.
Conclusions:
- Precision oncology continues to evolve with significant 2024 advancements.
- Improved molecular profiling enhances patient selection for targeted therapies.
- Novel drug development and repurposing strategies promise more effective cancer treatments.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

